Constellation Pharmaceuticals (Constellation Pharmaceuticals) Price-to-Tangible-Book : 4.32 (As of May. 12, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-12), Constellation Pharmaceuticals's share price is $33.99. Constellation Pharmaceuticals's Tangible Book per Share of Mar. 2021 for the quarter that ended in Mar. 2021 was $7.88. Hence, Constellation Pharmaceuticals's Price to Tangible Book Ratio of today is 4.32.

The historical rank and industry rank for Constellation Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

CNST' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.99 Med: 3.35 Max: 5.82
Current: 4.31

During the past 5 years, Constellation Pharmaceuticals's highest Price to Tangible Book Ratio was 5.82. The lowest was 0.99. And the median was 3.35.

CNST's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.7 vs CNST: 4.31

A closely related ratio is called PB Ratio. As of today, Constellation Pharmaceuticals's share price is $33.99. Constellation Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2021 was $7.88. Hence, Constellation Pharmaceuticals's P/B Ratio of today is 4.32.

Constellation Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Constellation Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals Price-to-Tangible-Book Chart

Constellation Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Price-to-Tangible-Book

0.99

5.82

3.35

Constellation Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Price-to-Tangible-Book	Get a 7-Day Free Trial													4.17	3.02	2.18	3.35	2.97

Competitive Comparison of Constellation Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Constellation Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Constellation Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Constellation Pharmaceuticals's Price-to-Tangible-Book falls into.

Constellation Pharmaceuticals Price-to-Tangible-Book Calculation

Constellation Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2021 )
	=	33.99	/	7.875
	=	4.32

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Constellation Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 First Street, Suite 200, Cambridge, MA, USA, 02142

Website

http://www.constellationpharma.com

Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.

Executives

Emma Reeve	officer: Chief Financial Officer	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine	officer: See Remarks	C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith	director, 10 percent owner	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey	officer: Chief Medical Officer	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu	director	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia	director	215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha	director, officer: See Remarks	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer	officer: Chief Scientific Officer	215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158